2 ASX healthcare shares to buy next week

CSL Limited (ASX:CSL) and this ASX healthcare shares could be the ones to buy right now. Here’s what you need to know…
The post 2 ASX healthcare shares to buy next week appeared first on The Motley Fool Australia. –

Doctor with stethoscope in hand and data graph showing upward trend

One area of the share market that has been performing consistently well in recent years is the healthcare sector. Since this time in 2015, the S&P/ASX 200 Health Care index has generated a return of 122% for investors.

This has been underpinned by increasing demand, better technologies and treatments, and ageing populations.

Pleasingly, these tailwinds aren’t going away any time soon. In light of this, it is no surprise to learn that the sector has been tipped as a great place to invest over the 2020s.

But which healthcare shares should you buy? Here are two highly rated options:

CSL Limited (ASX: CSL)

CSL is one of the world’s leading biotherapeutics companies. It has been an exceptionally positive performer over the last decade thanks to a combination of acquisitions, its research and development (R&D) activities, growing plasma collection network, and its leading therapies. Its portfolio of therapies currently includes the likes of Privigen, Hizentra, Idelvion, and Afstyla. Though, this will be boosted further in the coming years thanks to its almost billion-dollar annual investment in R&D.

UBS appears confident that this strong form can continue. The broker recently retained its buy rating and $346.00 price target on the company’s shares. While it notes that plasma collection conditions are tough in some markets because of COVID-19, it remains positive on its outlook. Especially given how it has a range of options to mitigate this headwind and a burgeoning R&D pipeline. 

Pro Medicus Limited (ASX: PME)

Pro Medicus is healthcare technology company that provides radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualisation solutions to healthcare organisations across the globe.

Due to the quality of its software, its sizeable market opportunity, and the shift away from legacy systems, Pro Medicus has been tipped to have a big future.

One broker that is positive on the company is Morgans. This month the broker retained its add rating and lifted its price target on the company’s shares to $35.02. It made the move after the company announced the signing of a five-year contract with MedStar Health worth a total of A$18 million.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of June 30th

More reading

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. recommends Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post 2 ASX healthcare shares to buy next week appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!